[ET Net News Agency, 24 April 2026] Morgan Stanley lowered the target price for Sh Pharma (02607) to HKD15.8 from HKD16 and maintained the "overweight" rating.
The research house said following the 2025 results, it cuts 2026-30 earnings estimates by 2-3% to reflect lower revenue assumptions. (rc)
The research house said following the 2025 results, it cuts 2026-30 earnings estimates by 2-3% to reflect lower revenue assumptions. (rc)